Images List Premium Download Classic

Natural Killer Cell

Natural Killer Cell-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods and compositions for natural killer cells
University Of Central Florida Research Foundation, Inc.
November 09, 2017 - N°20170319659

The application provides new compositions and methods for stimulating the production of natural killer (nk) cells in a subject. Nk cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of nk cells in proximity to a ...
Method for culturing natural killer cells using t cells
Mogam Institute For Biomedical Research
November 09, 2017 - N°20170319621

The present invention relates to a method for producing natural killer cells using t cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using cd4(+) t cells as feeder cells. The method for producing natural killer cells using t cells according to the present invention is a method capable of producing natural ...
Antibodies to tigit
Abmuno Therapeutics Llc
October 05, 2017 - N°20170281764

The invention provides monoclonal antibodies that specifically bind to tigit. The monoclonal antibodies have the capacity for substantial activation of t cells and natural killer cells by inhibiting binding of tigit to cd155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
Natural Killer Cell Patent Pack
Download + patent application PDFs
Natural Killer Cell Patent Applications
Download + Natural Killer Cell-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Natural Killer Cell-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Therapeutic combination of pi3k inhibitor and a btk inhibitor
Acerta Pharma B.v.
September 21, 2017 - N°20170266191

In some embodiments, the invention includes a therapeutic combination of a phosphoinositide 3-kinase (pi3k) inhibitor, including pi3k inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, and a bruton's tyrosine kinase (btk) inhibitor. In some embodiments, the invention includes therapeutic methods of using a btk ...
Antagonism of the vip signaling pathway
Emory University
September 14, 2017 - N°20170258904

Inhibition of the vip signaling pathway with vip antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a vip antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood ...
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
Acerta Pharma B.v.
August 17, 2017 - N°20170231995

In certain embodiments, the invention includes therapeutic methods of using a btk inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper t cells, cytotoxic t cells, regulatory t cells, natural killer cells, myeloid-derived suppressor cells, regulatory b cells, neutrophils, dendritic cells, and fibroblasts.
Natural Killer Cell Patent Pack
Download + patent application PDFs
Natural Killer Cell Patent Applications
Download + Natural Killer Cell-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Natural Killer Cell-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Smart car devices and de car polypeptides for treating disease and methods for enhancing immune ...
Chimera Bioengineering, Inc.
June 08, 2017 - N°20170157176

In an aspect, the present invention relates generally to the field of treating disease with car devices, smart car devices, de car devices, and/or smart-de car devices. The present invention also relates generally to the genetic modification of cytotoxic t-lymphocytes to reduce target cell killing by apoptosis and/or increase production of lytic proteins at desired times. In an ...
Ship inhibition to induce activation of natural killer cells
The Research Foundation For The State University Of New York
June 01, 2017 - N°20170151262

The present invention relates to the use or ship1 inhibitors and pan-ship1/2 inhibitors in various methods, including, without limitation, a method of inhibiting ship to induce broad activation of natural killer (nk) cells to treat various diseases.
Modified natural killer cells having anti-fugetactic properties and uses thereof
The General Hospital Corporation Dba Massachusetts General Hospital
April 13, 2017 - N°20170100433

This invention provides ex vivo methods for making modified natural killer cell compositions having overall anti-fugetactic properties for the effective and efficient treatment of tumors or cancers in a patient, and compositions and use thereof.
Development of natural killer cells and functional natural killer cell lines
University Of Utah Research Foundation
March 23, 2017 - N°20170081637

The invention relates to natural killer cells and methods for the development of immortalized natural killer cells and use of the natural killer cells. A growth and culture system is described that supports increased natural killer cell development, and provides for the establishment of continuous natural killer cell lines. Additionally, the disclosed method for generating natural killer cells may be ...
Regulatable chimeric antigen receptor
The Trustees Of The University Of Pennsylvania
March 23, 2017 - N°20170081411

Provided are compositions and methods relating to regulatable chimeric antigen receptors (rcars), natural killer cell receptor cars (nkr-cars), and regulatable nkr-cars (rnkr-cars), where the intracellular signaling or proliferation of the rcar or rnkr-car can be controlled to optimize the use of an rcar/nkr-car- or rnkr-car-expressing cell to provide an immune response. Cells can be engineered to express a rnkr-car ...
Modified natural killer cells and uses thereof
St. Jude Children's Research Hospital, Inc.
March 16, 2017 - N°20170073638

The present invention provides, in certain aspects, a natural killer (nk) cell that expresses all or a functional portion of interleukin-15 (il-15), and methods for producing such cells. The invention further provides methods of using a natural killer (nk) cell that expresses all or a functional portion of interleukin-15 (il-15) to treat cancer in a subject or to enhance expansion ...
Compositions and methods for anti-lyst immunomodulation
Research Institute At Nationwide Children's Hospital
March 16, 2017 - N°20170073401

Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the lyst protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage. Compositions and methods for ...
Natural Killer Cell Patent Pack
Download + patent application PDFs
Natural Killer Cell Patent Applications
Download + Natural Killer Cell-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Natural Killer Cell-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of generating natural killer cells
Anthrogenesis Corporation
January 05, 2017 - N°20170002322

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the nk cells produced by the method to an individual having the cancer or viral infection.
Modified natural killer cells, compositions and uses thereof
Fullhope Biomedical Co., Ltd.
November 10, 2016 - N°20160324895

Modified natural killer cells, pharmaceutical compositions comprising the modified natural killer cells and at least one pharmaceutically acceptable carrier or excipient, uses of the modified natural killer cells, and methods for identifying depleted natural killer cells and culturing the modified natural killer cells are provided.
Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
Anthrogenesis Corporation
October 06, 2016 - N°20160287635

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat ...
Neuronal modulation
The Rappaport Institute
October 06, 2016 - N°20160287577

A method for modulating an immune response by activating or inhibiting dopaminergic neurons in the ventral tegmental area (vta) is provided. Modulation is achieved by modulating the activity, the abundance or both of: a natural killer cell, a cd8 t-cell, a cd4 t-cell, a b-cell, a dendritic cell, a macrophage, a granulocyte, or their combination.
Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification ...
Nova Southeastern University
September 22, 2016 - N°20160275236

A general method of analyzing immune signaling networks for identification of potential therapeutic targets in complex, chronic medical disorders is described. The disclosure provides the cd3−/cd56+ natural killer (nk) cell population as a potential therapeutic target in the clinically-overlapping disorders gulf war illness (gwi) and myalg encephalomyelitis/chronic fatigue syndrome (me/cfs). The disclosure also provides a method ...
3d adcc nk facs assay
Hoffmann-la Roche Inc.
September 01, 2016 - N°20160252493

Herein is reported a cell analytical technology based on a three-dimensional spheroid/aggregate co-culture assay, wherein the spheroid or aggregate is formed of tumor and natural killer cells. This method is useful for the in vitro functional analysis of antibodies in single and high-throughput format.
Natural killer cells and methods for enhancing viability, proliferation and cytotoxicity of same following cryopreservation
Hoffmann-la Roche Inc.
June 30, 2016 - N°20160186138

The invention provides natural killer cells and improved methods for increasing natural killer cell viability, proliferation and cytotoxicity following cryopreservation.
Development of natural killer cells and functional natural killer cell lines
Hoffmann-la Roche Inc.
April 21, 2016 - N°20160109431

The invention relates to natural killer cells and methods for the development of immortalized natural killer cells and use of the natural killer cells. A growth and culture system is described that supports increased natural killer cell development, and provides for the establishment of continuous natural killer cell lines. Additionally, the disclosed method for generating natural killer cells may be ...
Loading